Anixa is focused on harnessing the bodyâs immune system in the fight against cancer. Anixaâs therapeutics portfolio includes a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T, and a cancer vaccine technology focused specifically on triple negative breast cancer (TNBC), the most lethal form of the disease. Anixaâs diagnostics portfolio includes the CchekTM liquid biopsy technology, a series of inexpensive non-invasive blood tests for early detection of solid tumors based on the bodyâs immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Source
No articles found.
Syros is redefining the power of small molecules to control the expression of gene...
Syros is redefining the power of small molecule...
Eniware, LLC provides portable, power-independent medical instrument sterilization...
Eniware, LLC provides portable, power-independe...
Ambu A/S engages in the development, production, and marketing of diagnostic and l...
Ambu A/S engages in the development, production...
Siemens Healthineers AG is the holding company of the Siemens Healthineers group. ...
Siemens Healthineers AG is the holding company ...
Join the National Investor Network and get the latest information with your interests in mind.